Shares in Issues & Shareholder Information
SkinBioTherapeutics plc is listed on the Alternative Investment Market (AIM) of the London Stock Exchange. The Company has not applied or agreed to have any of it securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms.
Issued share capital: 259,168,671 Ordinary Shares of 1p nominal value.
The percentage of Ordinary Shares not being held in public hands is 27.4% (Shares not being held in public hands includes members of the board and shareholders who own more than 10% of the issued voting share capital).
Shares held in treasury: Nil Ordinary shares.
There are no restrictions on the transfer of Ordinary Shares in the Company.
As an AIM traded UK registered company, SkinBioTherapeutics plc is subject to the UK City Code on Takeovers and Mergers legislation.
Significant Shareholders
As at 01 April 2026 significant shareholders that hold more than 3% of the share capital of SkinBioTherapeutics plc are detailed below:
| Name | Number Ordinary Shares | % |
|---|---|---|
| Mark and Diana Dixon | 69,900,000 | 26.97% |
| David Brierwood | 16,539,989 | 6.38% |
| Tyndall Investment Management | 15,223,381 | 5.87% |
| Seneca Partners Limited | 8,409,913 | 3.24% |
| Unicorn Asset Management | 7,894,737 | 3.05% |
Director Shareholders
| Name | Number Ordinary Shares | % |
|---|---|---|
| Martin Hunt* | 560,417 | 0.22% |
| Dr Cathy Prescott | 181,112 | 0.07% |
*Martin Hunt’s shareholding is held through Invictus Management Limited, a company controlled by Mr Hunt. Of the 560,417 shares held by Invictus Management Limited, 11,112 are held on behalf of Louise Hunt and 11,111 are held on behalf of Oliver Hunt.